We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BBT-877

News List

Bridge Biotherapeutics terminates collaboration agreement with Boehringer pharmaceutical-technology
November 11, 2020
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed to terminate their previously signed collaboration and licence agreement to develop BBT-877.
Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic pulmonary fibrosis expresspharma
November 10, 2020
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877.
Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline contractpharma
July 24, 2019
Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877.